Akashi Takuya, Koizumi Keiichi, Tsuneyama Koichi, Saiki Ikuo, Takano Yasuo, Fuse Hideki
Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Cancer Sci. 2008 Mar;99(3):539-42. doi: 10.1111/j.1349-7006.2007.00712.x. Epub 2008 Jan 14.
The chemokine receptor CXCR4 has been reported to be aberrantly expressed in human cancers and has also been shown to participate in the development of cancer metastasis. The present study was carried out to assess immunohistochemically the pattern of CXCR4 expression in patients with metastatic prostate cancer. We analyzed whether there may be an association between CXCR4 expression and prognosis. Fifty-two patients who received hormonal therapy were enrolled. Specimens were obtained from transperineal needle biopsy before treatment, and were stained with antihuman CXCR4 antibody. We also evaluated the pathological grade, extent of bony metastasis, clinical response to hormonal therapy, and patient prognosis. CXCR4 was detected in 94.2% patients. Its expression showed no association with pathological grade, extent of bony metastasis, or clinical response to hormonal therapy. Patients with a high expression of CXCR4 in tumors had poorer cancer-specific survival than those with low expression of CXCR4. CXCR4 expression is a useful prognostic factor for patients with metastatic prostate cancer treated with androgen-withdrawal therapy.
据报道，趋化因子受体CXCR4在人类癌症中异常表达，并且还参与癌症转移的发展。本研究旨在通过免疫组织化学方法评估转移性前列腺癌患者中CXCR4的表达模式。我们分析了CXCR4表达与预后之间是否可能存在关联。纳入了52例接受激素治疗的患者。在治疗前经会阴穿刺活检获取标本，并用抗人CXCR4抗体进行染色。我们还评估了病理分级、骨转移程度、对激素治疗的临床反应以及患者预后。94.2%的患者检测到CXCR4。其表达与病理分级、骨转移程度或对激素治疗的临床反应无关。肿瘤中CXCR4高表达的患者比CXCR4低表达的患者具有更差的癌症特异性生存率。CXCR4表达是接受去雄激素治疗的转移性前列腺癌患者的一个有用的预后因素。
